Viral myocarditis (VM) is a clinically common inflammatory disease. Accumulating literature has indicated that M2 macrophages protect mice from Coxsackievirus B3 (CVB3)-induced VM. However, mechanisms that underlie M2 macrophages alleviating myocardial inflammation remain largely undefined. We found that M2 macrophage-derived exosomes (M2-Exo) can effectively attenuate VM. The long non-coding RNA (lncRNA) AK083884 in M2-Exo was found to be involved in the regulation of macrophage polarization by exosome lncRNA sequencing combined with in vitro functional assays. M2-Exo-derived AK083884 promotes macrophage M2 polarization and protects mice from CVB3-induced VM. Furthermore, we identified pyruvate kinase M2 (PKM2) as a protein target binding to AK083884 and found that PKM2 knockdown could promote macrophages to polarize to M2 phenotype. Intriguingly, functional assay revealed that downregulation of AK083884 promotes metabolic reprogramming in macrophages. In addition, co-immunoprecipitation was performed to reveal AK083884 could interact with PKM2 and inhibition of AK083884 can facilitate the binding of PKM2 and HIF-1α. Collectively, our findings uncovered an important role of M2-Exo-derived AK083884 in the regulation of macrophage polarization through metabolic reprogramming, identified a new participant in the development of VM and provided a potential clinically important therapeutic target.
Group 2 innate lymphoid cells (ILC2s) promote the recruitment of eosinophils by secreting large amounts of type 2 cytokines (IL-5 and IL-13), thus triggering the main feature of asthma, pathological inflammation. Recent insights from mouse and human studies indicated a potential relationship between ILC2s and macrophages. However, the mechanism by which lung M2 macrophage-derived extracellular vesicles (M2 EVs) regulate ILC2s remains unclear. Here the size, morphology and specific markers of M2 EVs were successfully characterized in the lungs. Furthermore, we discovered that M2 EVs strongly promoted type 2 immune inflammation induced by papain. Mechanistically, M2 EVs were internalized by ILC2s, triggering ILC2s activation and inducing pro-inflammatory cytokine (IL-5 and IL-13) production. M2 EVs also indirectly enhanced the function of ILC2s through macrophages and CD4+ T cells. Using RNA sequencing, we found that long non-coding RNA 4930474H06Rik participated in mediating these effects of M2 EVs. Further mechanistic studies have elucidated the underlying mechanism by which 4930474H06Rik influences the function of ILC2s. Inhibition of 4930474H06Rik significantly altered the intracellular metabolic status of activated ILC2s and effectively alleviated airway inflammation in a mouse model of asthma. Taken together, we demonstrated that M2 EVs promoted allergic airway inflammation at least partially through 4930474H06Rik, implying that 4930474H06Rik can be considered as a therapeutic target for ILC2s activation in allergic airway inflammation.
CPVL (carboxypeptidase, vitellogenic-like) is a serine carboxypeptidase that was first characterized in human macrophages. However, the function of CPVL remains unclear in a variety of tumors. The quantitative PCR (qPCR), Western blotting, and IHC assays were utilized to measure the CPVL expression. CPVL was significantly upregulated in glioma cells and tissues compared with normal cells and tissues, respectively. Moreover, high CPVL expression was correlated with advanced clinical grade and poor prognosis. Silencing of CPVL promoted glioma cell apoptosis, and it inhibited cell proliferation and tumorigenicity in vitro and in vivo. Ingenuity Pathway Analysis (IPA) demonstrated that CPVL silencing activated the IFN-γ/STAT1 signaling pathway, thereby inducing glioma cell apoptosis. Mechanistically, immunopurification, mass spectrometry, IP, and glutathione S-transferase (GST) pull-down experiments elucidated that CPVL physically interacts with Bruton’s tyrosine kinase (BTK) and downregulates the STAT1 phosphorylation through promoting p300-mediated STAT1 acetylation. Our findings reveal the crucial role of CPVL in promoting the progression of glioma through suppressing STAT1 phosphorylation. CPVL might serve as a potential prognostic biomarker and therapeutic target for the treatment of glioma.
Exosome-derived long non-coding RNAs (lncRNAs) have emerged as promising diagnostic biomarkers in various diseases. However, their diagnostic potential in systemic lupus erythematosus (SLE) remains largely unexplored. This study aimed to characterize plasma exosomal lncRNA profiles and identify candidate lncRNAs with diagnostic and disease-monitoring potential in SLE. Plasma exosomes were isolated from SLE patients and healthy controls (HCs), followed by high-throughput sequencing to characterize exosomal lncRNA expression profiles. Differentially expressed lncRNAs were identified and subsequently validated using quantitative real-time PCR (qRT-PCR). Correlations between the validated exosomal lncRNAs and clinical indicators of SLE were assessed. Receiver operating characteristic (ROC) curve and multivariate logistic regression analyses were performed to evaluate the diagnostic performance of the identified lncRNAs. Three plasma-derived exosomal lncRNAs—ENSG00000229882, MIR4713HG, and LINC00620—were significantly upregulated in SLE patients compared with HCs. Logistic regression analysis identified MIR4713HG and LINC00620 as predictors of SLE. A combined diagnostic model incorporating these two lncRNAs demonstrated diagnostic capacity for distinguishing SLE patients from HCs, with an area under the curve (AUC) of 0.759. Notably, exosomal LINC00620 expression was significantly upregulated in patients with active SLE compared with those with inactive disease and showed a positive correlation with SLE Disease Activity Index 2000 (SLEDAI-2 K scores). Plasma exosomal ENSG00000229882, MIR4713HG, and LINC00620 were significantly upregulated in SLE, indicating their potential as non-invasive diagnostic biomarkers. Particularly, LINC00620 showed a positive correlation with disease activity, suggesting its clinical utility for both SLE diagnosis and disease monitoring.